| Code | CSB-RA003995MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Omoprubart, targeting the complement component 5 (C5) protein. C5 plays a central role in the complement cascade, a critical component of the innate immune system. Upon activation, C5 is cleaved into C5a and C5b fragments, where C5a functions as a potent anaphylatoxin promoting inflammation, while C5b initiates formation of the membrane attack complex (MAC) that can cause cell lysis. Dysregulated C5 activation has been implicated in numerous complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorders.
Omoprubart represents a therapeutic antibody developed to inhibit C5 cleavage, thereby preventing downstream complement activation and associated tissue damage. This biosimilar antibody provides researchers with a valuable tool for investigating C5-mediated pathways, studying complement system biology, evaluating therapeutic mechanisms in complement-related diseases, and developing novel intervention strategies. It serves as an essential reagent for laboratories focused on immunology, inflammation research, and complement-associated pathological conditions.
There are currently no reviews for this product.